Meeting
2019 ASCO Annual Meeting
Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy.
Authors
Emily Hinchcliff
The University of Texas MD Anderson Cancer Center, Houston, TX
Emily Hinchcliff , Weiyi Peng , Virginia Bayer , Cara L. Haymaker , Steven Y Huang , Rahul Sheth , Shannon Neville Westin , Karen H. Lu , Patrick Hwu , Amir A. Jazaeri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03508570
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5606)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5606
Abstract #
TPS5606
Poster Bd #
423a
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
First Author: John H. Sampson
Poster
2014 ASCO Annual Meeting
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
First Author: John Howard Sampson
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
First Author: Patrick Walsh McGarrah
Poster
2023 ASCO Annual Meeting
Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.
First Author: Rosemary Senguttuvan